Management of Severe Hyponatraemia (Serum Sodium ≈ 122 mmol/L)

1. Immediate Initial Actions

• Discontinue all diuretics without delay; this is the first critical step regardless of the underlying cause. 1
• Restrict free‑water intake to roughly 1 L per day to prevent further dilution of serum sodium. 2
• Obtain urgent laboratory studies including serum osmolality, creatinine, urine sodium and urine osmolality. 3
• Perform a bedside volume‑status assessment (orthostatic hypotension, jugular venous distension, peripheral edema, ascites, skin turgor). 3

2. Decision Framework: Volume Status + Renal Function

• Management hinges on two parameters: clinical volume status (hypovolaemic, euvolaemic, hypervolaemic) and renal function (creatinine level/trend). 1

2.1. Elevated or Rising Creatinine (>150 µmol/L ≈ 1.7 mg/dL)

• Indicates impending renal failure and mandates immediate volume expansion, irrespective of serum sodium. [1][4]
• Administer intravenous isotonic saline; in cirrhosis, 5 % albumin is preferred. 1
• Alternative colloids (gelofusine, haemaccel, voluven) are acceptable if albumin unavailable. [1][4]
• Rationale: Effective hypovolaemia drives ADH secretion; water restriction alone would worsen haemodynamics and risk irreversible renal injury. [1][4]
• Monitor serum sodium every 4–6 hours during active treatment. 3

2.2. Normal and Stable Creatinine

• Management is guided primarily by volume status.

2.2.1. Hypovolaemic Presentation (no ascites/edema, orthostatic changes)

• Volume expansion with normal saline is the treatment of choice. 4
• Identify and correct the underlying aetiology (gastro‑intestinal losses, cerebral salt‑wasting, diuretic over‑use, adrenal insufficiency). 3

2.2.2. Euvolemic or Hypervolemic Presentation (ascites, edema present)

• Continue strict free‑water restriction to 1–1.5 L daily. 2
• In cirrhotic patients, add hyper‑oncotic albumin infusion to mobilise fluid and suppress ADH release. 2
• Limit dietary sodium to ≈ 90 mmol/day (≈ 5 g). [1][4]
• Do not rely on water restriction alone in cirrhosis with ascites; this may paradoxically worsen effective hypovolaemia and ADH secretion. [1][4]

3. Safe Sodium‑Correction Rate

• An absolute ceiling of 8 mEq/L per 24 h is recommended; exceeding this markedly raises the risk of osmotic demyelination syndrome (ODS). 1

4. Clinical Scenarios

4.1. Cirrhosis with Ascites

• Stop diuretics, restrict water to 1 L/day, and add albumin infusion. 2
• Hypertonic saline should be avoided unless the patient is severely symptomatic (seizures, coma), as it can worsen volume overload. [5][6]
• For a sodium of 122 mmol/L with normal creatinine, a cautious approach—stopping diuretics—is considered safer than continuation. [1][4]

4.2. Neurosurgical Patients (Cerebral Salt‑Wasting vs. SIADH)

• Distinguish cerebral salt‑wasting from SIADH by assessing volume status. 3
• Cerebral salt‑wasting requires aggressive volume expansion with hypertonic saline and fludrocortisone. 3
• SIADH is managed with fluid restriction. 3

4.3. Vasopressin‑Receptor Antagonists (Vaptans)

• Tolvaptan may be used short‑term (≤ 30 days) for euvolemic or hypervolemic hyponatraemia unresponsive to fluid restriction. 6
• Initiation must occur in‑hospital with intensive monitoring; outpatient start is contraindicated. 6

4.4. Hypertonic Saline (3 % NaCl)

• Reserve for symptomatic hyponatraemia (seizures, altered mental status, coma). 3
• If employed, correct 5–6 mEq/L over the first 6 hours (or until symptoms resolve), then adopt a slower correction rate. 3

5. Monitoring Protocol

• Serum sodium: every 4–6 hours during active correction, then daily once stable. 3
• Daily weight and strict intake/output charting. [3][2]
• Renal function (creatinine): every 2–3 days during therapy. [1][4]

6. Special Populations

6.1. Patients Awaiting Liver Transplantation

• Severe hyponatraemia (< 120 mEq/L) markedly increases ODS risk during intra‑operative large‑volume resuscitation. [1][4]
• Multidisciplinary coordination (nephrology, hepatology, transplant surgery) is essential. 2
• Hypertonic saline may be considered if transplantation is imminent, but rapid correction should be avoided. 5

All facts are derived from peer‑reviewed sources and attributed to the cited references.

Management of Moderate Hyponatremia (Serum Sodium ≈ 122 mEq/L)

Immediate Actions

• Discontinue all diuretics, restrict free water to ≈ 1 L/day, and assess renal function and volume status before deciding on volume expansion – strong recommendation from the 2021 AASLD Hyponatremia guideline (Hepatology)【@1】.

Assessment of Volume Status & Renal Function

• Determine volume status (hypovolemic vs. euvolemic/hypervolemic) and measure serum creatinine promptly – essential step in the 2006 Gut guideline algorithm【@2】【@3】【@4】.
• Elevated or rising creatinine (>150 µmol/L or >1.7 mg/dL) indicates impending renal failure and mandates immediate volume expansion – moderate‑strength recommendation (Gut 2006)【@2】【@3】【@4】.
• Normal, stable creatinine permits conservative management with water restriction alone – moderate‑strength recommendation (Gut 2006)【@2】【@3】.

Volume‑Status‑Based Treatment

Hypovolemic (Elevated/Rising Creatinine)

• Initiate volume expansion immediately:
  
  • 5 % albumin (preferred in cirrhosis)【@1】.
  • Normal saline or lactated Ringer’s as alternatives【@1】.
  • Colloid solutions (e.g., gelofusine, Haemaccel) are acceptable options【@2】【@3】【@4】.
• Rationale – effective hypovolemia drives ADH secretion; further water restriction would worsen hemodynamics and risk irreversible renal failure【@2】【@3】.

Euvolemic / Hypervolemic (Normal Creatinine)

• Restrict free water to ≈ 1 L/day – cornerstone of therapy per AASLD guideline【@1】.
• In cirrhotic patients, add hyperoncotic albumin infusion to mobilize fluid and blunt ADH release – strong recommendation (Hepatology 2021; supported by Gastroenterology 2025)【@1】【@6】.
• Limit dietary sodium to ≈ 90 mmol/day (≈ 5.2 g) in cirrhosis – moderate recommendation (Gut 2006)【@2】.

Correction Rate & Safety Parameters

• Do not exceed a rise of 4–6 mEq/L per 24 h; absolute ceiling = 8 mEq/L per 24 h to prevent osmotic demyelination syndrome (ODS)【@1】.
• AASLD 2021 guideline specifically recommends 4–6 mEq/L/day for high‑risk groups (cirrhosis, malnutrition, alcoholism)【@1】.
• Monitor serum sodium every 4–6 hours during active correction – strong recommendation (Hepatology 2021; reinforced by Neurosurgery 2009)【@1】【@7】.

Management of Over‑correction

• Administer desmopressin or free‑water (electrolyte‑free) to re‑lower serum sodium【@1】.
• Consider intravenous tromethamine as an adjunct to mitigate ODS risk【@1】.

Advanced Therapeutic Options (Refractory Cases)

Vasopressin‑Receptor Antagonists (Vaptans)

• Tolvaptan may be used short‑term (≤30 days) for euvolemic or hypervolemic hyponatremia unresponsive to fluid restriction【@1】.
• Because vaptans can cause unpredictable rapid sodium rises, they require intensive monitoring and should be avoided in patients at high ODS risk【@1】.

Hypertonic Saline

• Reserve 3 % saline for symptomatic hyponatremia (seizures, altered mental status, coma) or when imminent liver transplantation demands rapid correction【@1】【@7】.
• In asymptomatic patients with sodium ≈ 122 mEq/L, hypertonic saline is not indicated【@1】.

Monitoring Protocol

• Serum sodium: every 4–6 hours initially, then daily once stable【@1】【@7】.
• Daily weight and intake/output charting to track volume status【@7】【@6】.
• Renal function (creatinine): every 2–3 days during therapy【@2】【@3】.
• Watch for delayed ODS signs (dysarthria, dysphagia, altered consciousness, weakness 2–7 days after correction)【@1】.

Special Populations

Cirrhotic Patients

• Adopt a more conservative correction strategy due to heightened ODS susceptibility【@1】.
• Prefer albumin over crystalloid for volume expansion【@1】【@6】.
• If hyponatremia remains refractory, evaluate for liver transplantation【@1】【@6】.

Patients Awaiting Transplant

• Severe hyponatremia (<120 mEq/L) markedly increases ODS risk during intra‑operative large‑volume resuscitation【@2】【@1】.
• Coordinate care among nephrology, hepatology, and transplant surgery teams【@1】【@6】.

Evidence‑Based Recommendations for Hyponatremia Management in Cirrhosis and SIADH

Dietary Sodium Restriction

• Limit dietary sodium to roughly 90 mmol per day (≈5 g) to aid control of hypervolemic hyponatremia in patients with liver disease. Level of evidence not specified. 7

Vasopressin‑Receptor Antagonist (Vaptan) Therapy

• Tolvaptan may be employed for ≤30 days in euvolemic or hypervolemic hyponatremia that does not respond to fluid restriction. Level of evidence not specified. 7
• Initiation of tolvaptan must occur in‑hospital with intensive monitoring; outpatient initiation is contraindicated because of the risk of unpredictable rapid sodium rises. Level of evidence not specified. 7

Multidisciplinary Management of Refractory Hyponatremia

• Recurrent or refractory hyponatremia should trigger a multidisciplinary review involving nephrology, hepatology, and the liver‑transplantation team. Level of evidence not specified. 7
• In cases of severe volume overload or renal failure, consider intravenous vasoconstrictor therapy (e.g., terlipressin), carefully monitored hypertonic saline boluses, or renal replacement therapy as adjuncts. Level of evidence not specified. 7

Outpatient Management of Asymptomatic Hypervolemic Hyponatremia (Cirrhosis)

• Implement sodium and water restriction (target fluid intake ≈1–1.5 L/day). Level of evidence not specified. 7
• Adjust or discontinue diuretics and laxatives as needed to avoid further sodium and water imbalance. Level of evidence not specified. 7
• Perform regular electrolyte monitoring to detect changes promptly. Level of evidence not specified. 7

Inpatient Management of Severe or Symptomatic Hypervolemic Hyponatremia (Cirrhosis)

• Continue sodium and water restriction during hospitalization. Level of evidence not specified. 7
• Modify or stop diuretics and laxatives based on volume assessment. Level of evidence not specified. 7
• Use intravenous albumin (or oral vasoconstrictor therapy) guided by volume status to improve circulatory function and support sodium correction. Level of evidence not specified. 7

Large‑Volume Paracentesis Protocol

These recommendations aim to prevent post‑paracentesis circulatory dysfunction. Level of evidence not specified. 7

Management of Refractory Ascites and Hyponatremia

• Refer well‑selected patients for transjugular intrahepatic portosystemic shunt (TIPS) when ascites and hyponatremia remain uncontrolled despite optimal medical therapy. Level of evidence not specified. 7
• Evaluate candidacy for liver transplantation in patients with persistent hyponatremia unresponsive to other interventions. Level of evidence not specified. 7